Published Papers & Misc - UMEZAWA Yoshihiro

Division display  21 - 31 of about 31 ／  All the affair displays >>

  1. 田畑 真梨子, 佐藤 悠佑, 木暮 泰寛, McClure Marni B., 斎藤 優樹, 新垣 清登, 吉藤 康太, 古屋 淳史, 河野 隆志, 白石 友一, 久米 春喜, 片岡 圭亮. がん分子標的治療薬・がん免疫治療薬への抵抗性に関わる分子機構とその克服　遺伝性淡明細胞型腎細胞癌における腫瘍内または腫瘍間の遺伝的、免疫的不均一性 日本癌学会総会記事. 2020.10; 79回 S4-3. ( ichushi )

  2. 古屋 淳史, 斎藤 優樹, 亀田 拓郎, 木暮 泰寛, McClure Marni B., 新垣 清登, 吉藤 康太, 田畑 真梨子, 下田 和哉, 片岡 圭亮. がんの一細胞生物学　マルチオミクス単一細胞解析によるHTLV-1感染状態およびATLにおける細胞動態の網羅的解明 日本癌学会総会記事. 2020.10; 79回 S12-3. ( ichushi )

  3. Masahide Yamamoto, Keisuke Tanaka, Yoshihiro Umezawa, Toshikage Nagao, Shigeo Toyota, Osamu Miura. Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy. Anticancer Res.. 2019.09; 39 (9): 5115-5122. ( PubMed, DOI )

  4. Kota Yoshifuji, Yoshihiro Umezawa, Ayako Ichikawa, Ken Watanabe, Osamu Miura, Masahide Yamamoto. Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases. In Vivo. 2019.09; 33 (5): 1599-1604. ( PubMed, DOI )

  5. Akiyama Hiroki, Umezawa Yoshihiro, Ishida Shinya, Okada Keigo, Nogami Ayako, Miura Osamu. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress CANCER LETTERS. 2019; 453 84-94. ( PubMed, DOI )

  6. Ayako Nogami, Keigo Okada, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway. Transl Oncol. 2018.11; 12 (2): 336-349. ( PubMed, DOI )

  7. Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Gaku Oshikawa, Toshikage Nagao, Osamu Miura. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget. 2018.06; 9 (42): 26834-26851. ( PubMed, DOI )

  8. Keigo Okada, Ayako Nogami, Shinya Ishida, Hiroki Akiyama, Cheng Chen, Yoshihiro Umezawa and Osamu Miura. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway Oncotarget. 2017.12; 9 8870-8886.

  9. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1). Journal of Biological Chemistry. 2017.12; 292 (48): 19639-19655.

  10. Yoshihiro Umezawa, Tetsuya Kurosu, Hiroki Akiyama, Nang Wu, Ayako Nogami, Toshikage Nagao, Osamu Miusa. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016.06; ( PubMed )

  11. Hiroki Akiyama, Masahide Yamamoto, Chizuko Sakashita, Yoshihiro Umezawa, Tetsuya Kurosu, Naomi Murakami, Osamu Miura. Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D CBFB/MYH11 Developing after Exposure to Irinotecan-containing Chemoradiotherapy. Intern. Med.. 2015; 54 (6): 651-655. ( PubMed, DOI )

< PREV - NEXT >

  • 1
  • 2
To the head of this page.▲